Sign in
CompletedEarly phase 1

Carboprost (Hemabate) for Fibroid Resection

Key facts

Who runs it
Northwestern University
Where
Chicago, United StatesSee the site
Trial code
Status
Completed
Phase
Early phase 1
People taking part
19 people enrolled
Started
12 Jul 2022
Ended
6 May 2024
Type of study
Interventional
Treatments tested
  • Carboprost Tromethamine
Record updated
19 September 2024

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patients scheduled to undergo myomectomy with a surgeon in the division of Minimally Invasive Gynecologic Surgery
  • Ability to understand and the willingness to sign a written informed consent

Who cannot take part

  • If any oxytocic agents have been or will be administered prior to surgery
  • History of renal and/or hepatic impairment
  • Active cardiac disease, pulmonary disease, or pelvic inflammatory disease (PID)
  • Anemia (Hgb < 7g/dL), diabetes mellitus, jaundice, or epilepsy

Where in United States

  • Northwestern University - Northwestern Medicine, Lavin Family PavilionChicago, United States

About the trial

What the trial wants to find out

The purpose of this research study is to determine if low-dose (i.e., a fraction of what is commonly used) carboprost (Hemabate) helps facilitate fibroid removal (myomectomy).

The group in the trial

  • HemabateTreatment being tested

    Dilute the 250mcg/mL vial with 25mL saline to create a solution of 10mcg/mL, and inject no more than 10mL of diluted solution at the base of the fibroid. The route of administration depends on the location of the fibroid.

    Treatment: Carboprost Tromethamine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Carboprost Tromethamine (Hemabate) for Resection of Fibroids-a Pilot Study
Publications
Record updated
19 September 2024